Chandra Bhagat Pharma Ltd.

"We are a company based in India, responsibly offering pharmaceutical products across the globe!" We are a public listed company. We are associated with many companies worldwide. We export from India various API & intermediates, pharmaceutical products, critical care injections, plasma, blood, biological products across the globe. We import vaccines in India from the top most manufacturers of the world. We have our own marketing team in India. Our team promotes our brand pharmaceutical formulations, especially injectables We have an excellent sourcing & qualified supply & regulatory team.

Elfin Drugs Private Limited

Elfin Drugs Private Limited is a consumer services company based out of E-206 Industrial Area Phase 8 B S.A.S. Nagar, Mohali, Punjab, India.

Urihk Pharmaceutical Private Limited

Urihk Pharmaceuticals (“URIHK” or “Urihk”), a subsidiary of UREKA Hong Kong Ltd., has built a strong foundation in India by launching and distributing innovative drugs in the critical care segment. With a network spanning more than 55 countries, we are known for proliferating reliable and diverse therapies that make a real difference in people’s lives. Urihk began as a partnership between three highly experienced companies: Jiangsu Aidea Pharmaceutical (“Aidea”), Joint Force Pharmaceutical Limited (“JFPL”), and Shenzhen Mellow Hope Pharm Limited (“Mellow Hope”). The Urihk Partnership continues to grow and evolve, leveraging learnings and expertise to bring the best the world has on offer to India. Urihk’s mission is to help save lives through the development and distribution of groundbreaking products. We aim to provide innovative products at optimal pricing, to suit a wide range of customers in the critical care segment. Our top priority is always the requirements of medical professionals and their patients; at Urihk, we strive to emphasize the ‘U’ before the ‘I’. Urihk is entirely invested in becoming a leading name in the critical care/ICU segment, in India and beyond. We provide a unique product range for our extensive customers, and are constantly looking for better ways to connect with new partners globally. Count on us to fulfill the unmet needs of Indian patients. Count on us to help you build a better India.

mastelli bio-pharmaceutical company italy

Mastelli is a historical Italian bio-pharmaceutical company with 70 years of experience in the development, production, and marketing of polynucleotides (PN) and polydeoxyribonucleotides (PDRN) for medical applications. Mastelli is the originator company of DNA fractions usage in the world. Mastelli develops and produces internally the global range of PN and PDRN-based drugs and medical devices from raw materials to the sale and distribution of finished products. Mastelli is the only company in the world that has developed over the years a wide range of proposals that integrate DNA fractions with other technologies and are therefore able to offer innovative solutions and protocols for medical applications in several therapeutic areas (aesthetic medicine, orthopedics, gynecology, dermatology, and advanced wound care).

Symbio Proinnovera

The newly announced merger of NY-headquartered Symbio LLC and CA-headquartered Dow Development Laboratories LLC with Munster (Germany)-based Proinnovera will form Symbio Proinnovera, creating one of the world’s largest specialized dermatology-focused clinical research organizations. Founded over 20 years ago, the Symbio & Dow Group has a full-service clinical trial CRO offering for dermatology, complemented by a business active in the pre-clinical formulation of topicals, providing its client's dermatology and aesthetics services - from pre-clinical formulation work to subsequent clinical trial execution. Proinnovera was founded 25 years ago and is a leading European CRO in the dermatology clinical trial space. It is a full-service CRO conducting clinical studies from Phase I to IV, as well as non-interventional and medical device studies. Proinnovera turns study data into oversight for clients to accelerate decision-making, increasing transparency and efficiency in the conduct of clinical trials. Both companies are proven market leaders among specialty dermatology CROs with exceptional geographical coverage. Their combined strength will enable them to excel at addressing customers’ needs and expectations in all areas of research. The newly formed organization will leverage the combined power of two highly experienced teams with deep expertise in the dermatology space to generate efficiencies and accelerate clinical research. Symbio Proinnovera will be supported in its growth by ARCHIMED, a leading investment firm focused exclusively on healthcare industries.